The Oxford Structural Genomics Consortium (SGC) is a key member of a new consortium, “Enabling and Unlocking biology in the Open” (EUbOPEN), which has been awarded an Innovative Medicines Initiative grant worth over 66 million Euros. The project will last five years.
The EUbOPEN project builds on the efforts of the successful ULTRA-DD consortium previously led by the University of Oxford, and will be led by Goethe University Frankfurt, and the pharmaceutical company Boehringer Ingelheim. The consortium consists of 22 partners from academia and industry that will work together to develop high quality chemical tools that can be used to investigate the biology of disease and discover new targets for drug discovery. In keeping with the SGC commitment to open science, the project outputs will be made openly available to the research community, without restriction, including chemogenomic library sets, chemical probes, assay protocols and associated research data.
The research at the University of Oxford will be directed by Professor Chas Bountra, the Chief Scientific Officer of SGC Oxford and the University of Oxford’s Pro Vice-chancellor for innovation, and Dr Jon Elkins, Principal Investigator at SGC Oxford.